Mirage News
(Barcelona, Spain, Wednesday, 24 September 2025) New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.1 Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, was evaluated using real-world
Read More
Research: Ocrelizumab Tops in MS Relapse Control | Mirage News
Mirage News
22:27
(Barcelona, Spain, Wednesday, 24 September 2025) New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.1 Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, was evaluated using real-world
